Pipeline: IPI-940
Overview
IPI-940 is an orally administered inhibitor of fatty acid amide hydrolase, or FAAH, an enzyme that plays an important role in modulating pain and inflammatory responses. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory responses. As a novel inhibitor of FAAH, IPI-940 has potential application for the treatment of a broad range of painful conditions and inflammatory diseases.
Development Progress
In November 2010, we reported topline data from a Phase 1 randomized study of IPI-940 in healthy adult volunteers. The study assessed the pharmacokinetics, pharmacodynamics, safety and tolerability of IPI-940 following single oral administration at escalating dose levels. In the study, administration of IPI-940 resulted in marked FAAH inhibition and increased anandamide levels. In addition, IPI-940 was well tolerated, with no observed dose-limiting toxicities.
Collaboration Information
In November 2010, Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. exercised their right to assume worldwide development and commercialization activities for our FAAH program. Purdue expects to begin Phase 2 studies of IPI-940 in pain.